(MENAFN- PR Newswire)
NEW YORK, Aug. 30, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global primary ciliary dyskinesia market
size is estimated to grow by USD 160.2 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of
5.7%
during the forecast period. Increasing awareness of pcd conditions
is driving market growth,
with a trend towards
increasing pipeline projects on PCD. However,
high development costs of pcd treatments
poses a challenge. Key market players include Acare Technology Co. Ltd., Amgen Inc., AstraZeneca Plc, Bayer AG, Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., CHIESI Farmaceutici SpA, F. Hoffmann La Roche Ltd., Fitwel Pharmaceuticals Pvt. Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Medigene AG, Novartis AG, Pfizer Inc., ReCode Therapeutics, Regeneron Pharmaceuticals Inc., Rotech Healthcare Inc., Sanofi SA, and Teva UK Ltd..
Continue Reading
Technavio has announced its latest market research report titled Global primary ciliary dyskinesia market 2024-2028
Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report
| Primary Ciliary Dyskinesia Market Scope |
| Report Coverage |
Details |
| Base year |
2023 |
| Historic period |
- |
| Forecast period |
2024-2028 |
| Growth momentum & CAGR |
Accelerate at a CAGR of 5.7% |
| Market growth 2024-2028 |
USD 160.2 million |
| Market structure |
Fragmented |
| YoY growth 2022-2023 (%) |
5.24 |
| Regional analysis |
Europe, North America, Asia, and Rest of World (ROW) |
| Performing market contribution |
Europe at 37% |
| Key countries |
US, UK, Canada, Germany, Japan, and Switzerland |
| Key companies profiled |
Acare Technology Co. Ltd., Amgen Inc., AstraZeneca Plc, Bayer AG, Becton Dickinson and Co., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., CHIESI Farmaceutici SpA, F. Hoffmann La Roche Ltd., Fitwel Pharmaceuticals Pvt. Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Medigene AG, Novartis AG, Pfizer Inc., ReCode Therapeutics, Regeneron Pharmaceuticals Inc., Rotech Healthcare Inc., Sanofi SA, and Teva UK Ltd. |
Market Driver
Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder affecting the movement of cilia in the respiratory system. The market for PCD treatments is growing due to increasing awareness and diagnosis rates. Companies are investing in research and development of new therapies to improve patient outcomes. These include medications to clear mucus and correct cilia function, as well as airway clearance devices. Collaborations and partnerships between industry and academic institutions are also driving innovation in this field. The market is expected to expand with the launch of new products and increasing demand for effective treatments.
Primary Ciliary Dyskinesia (PCD), a genetic disorder affecting cilia function, is gaining attention in the healthcare industry. With a strong family history and genetic mutation as key indicators, early diagnosis through diagnostic techniques like Electron Microscopy and genetic testing is crucial. General practitioners, pediatricians, and pulmonary specialists play a vital role in identification and referral. FDA-approved treatments include antibiotics, bronchodilators, and anti-inflammatory medications. Breakthrough therapies like ENaC inhibitors and LNP-formulated mRNA show promise. Known complications include Kartagener syndrome, situs inversus, heterotaxy, and respiratory issues. Subject Matter Experts collaborate on research in hospitals & clinics and research centers. Disease-modifying treatments and therapeutic options continue to evolve. Healthcare systems employ telemedicine for accessibility. PCD impacts the respiratory tract, reproductive organs, and causes chronic respiratory issues, lung infections, and issues with ears and sinuses. Bronchiectasis is a common complication. Collaborative efforts in the industry aim to improve patient care and outcomes.
Explore a 360° Analysis of the Market: Unveil the Impact of AI. For complete insights- Request Sample!
Market
Challenges
Primary Ciliary Dyskinesia (PCD) is a rare, genetic disorder affecting the movement of tiny hair-like structures in the lungs and other organs. The market for PCD treatments is growing due to increasing awareness and diagnosis rates. Companies are developing new therapies to improve patient outcomes. These include mucolytics, which help thin and loosen mucus, and airway clearance devices, which aid in removing mucus from the lungs. Additionally, gene therapies are being explored to address the underlying cause of PCD. Overall, the market is expected to expand as new treatments become available.
Primary Ciliary Dyskinesia (PCD) is a rare, genetic disorder affecting the function of cilia and flagella in the respiratory tract, ears, sinuses, and reproductive organs. Diagnosis involves complex genetic testing, electron microscopy, and specialist expertise. Treatment includes antibiotics for lung infections, bronchodilators, anti-inflammatory medications, chest physical therapy, and mucolytic agents. Newer therapies like ENaC inhibitors, LNP-formulated mRNA, and gene therapies are under investigation. Challenges include access to specialized care in hospitals & clinics and research centers, affordability of drug treatment, and need for collaborative efforts between healthcare systems, academic institutions, and industry. Telemedicine and specialty clinics offer potential solutions. The World Health Organization emphasizes the importance of early diagnosis and appropriate care for this chronic condition.
For more insights on driver and challenges
-
Request a
sample report!
Segment Overview
This primary ciliary dyskinesia market report extensively covers market segmentation by
Type
1.1 Genetic testing
1.2 Electron microscopy
1.3 Nasal nitric Oxide (Nno) testing
Application
2.1 Hospitals
2.2 Speciality clinics
2.3 Research centers
Geography
3.1 Europe
3.2 North America
3.3 Asia
3.4 Rest of World (ROW)
1.1
Genetic testing-
Primary Ciliary Dyskinesia (PCD) is a rare, genetic disorder affecting the movement of cilia in the respiratory system. This condition impairs mucus clearance, leading to chronic lung infections and respiratory distress. The global market for PCD treatments is growing due to increasing awareness and diagnosis rates. Companies are developing new therapies, including corrective surgery and medications, to improve patient outcomes. Market size is expected to expand with rising demand for effective treatments.
For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) - Download a Sample Report
Research Analysis
Primary Ciliary Dyskinesia (PCD) is a rare, genetic disorder affecting the function of cilia and flagella in the respiratory tract, reproductive organs, and other areas. It is characterized by a family history of chronic respiratory issues, including lung infections, bronchiectasis, and issues with the ears and sinuses. Diagnostic techniques for PCD include electron microscopy, genetic testing, and assessing ciliary function. General practitioners, pediatricians, and pulmonary specialists are often the first point of contact for diagnosis and management. FDA-approved treatments include drug therapy, while breakthrough therapies are under investigation. Healthcare systems, including hospitals and telemedicine, play a crucial role in providing care for individuals with PCD. The World Health Organization recognizes PCD as a significant health concern, and ongoing research aims to improve understanding of the condition and develop new therapeutic options, including radiotherapy and chemotherapy. Genetic mutations in specific genes are known to cause PCD, and ongoing research focuses on identifying these mutations to aid in diagnosis and potential future treatments.
Market Research Overview
Primary Ciliary Dyskinesia (PCD) is a rare, genetic disorder affecting the structure and function of cilia and flagella in the respiratory tract, ears, sinuses, and reproductive organs. This condition is characterized by a family history of chronic respiratory issues, lung infections, and situs inversus or heterotaxy. Diagnostic techniques include electron microscopy, genetic testing, and assessment of ciliary ultrastructure. General practitioners, pediatricians, and pulmonary specialists are often the first point of contact for diagnosis and management. FDA-approved treatments include antibiotics, bronchodilators, anti-inflammatory medications, chest physical therapy, and mucolytic agents. Breakthrough therapies include ENaC inhibitors, LNP-formulated mRNA, and gene therapies. Subject Matter Experts play a crucial role in advancing research and development of disease-modifying treatments. The World Health Organization and various research centers, hospitals, and clinics are collaborating to improve diagnostic methods and develop new therapeutic options. Healthcare systems, academic institutions, and telemedicine platforms are also essential in providing access to specialized care for individuals with PCD.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
Type
Genetic Testing
Electron Microscopy
Nasal Nitric Oxide (Nno) Testing
Application
Hospitals
Speciality Clinics
Research Centers
Geography
Europe
North America
Asia
Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:
[email protected]
Website:
SOURCE Technavio
MENAFN30082024003732001241ID1108620867
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.